| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Nicholas P Restifo | |
| Zhiya Yu | |||
| James N Kochenderfer | |||
| Dorina Frasheri | |||
| P2860 | cites work | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells | Q24540135 |
| CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. | Q24540429 | ||
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 | ||
| Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses | Q29619908 | ||
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma | Q29622835 | ||
| In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes | Q71887324 | ||
| Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development | Q72087189 | ||
| Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development | Q72120139 | ||
| Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses | Q79401102 | ||
| Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo | Q33283678 | ||
| Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice | Q33560416 | ||
| Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli | Q33638891 | ||
| Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen | Q33791198 | ||
| Characterization and expression of the gene for the human Fc receptor gamma subunit. Definition of a new gene family | Q33840543 | ||
| Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity | Q34326400 | ||
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 | Q34360292 | ||
| Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. | Q34422330 | ||
| Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions | Q34669675 | ||
| The promise and potential pitfalls of chimeric antigen receptors | Q34970378 | ||
| Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Q35567244 | ||
| Peripheral tolerance of CD8 T lymphocytes | Q36076297 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Supernatural T cells: genetic modification of T cells for cancer therapy | Q36328805 | ||
| Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells | Q36346300 | ||
| Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis | Q36366675 | ||
| Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system | Q36713904 | ||
| Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells | Q36868712 | ||
| Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies | Q37022546 | ||
| Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor | Q37354362 | ||
| Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. | Q39749811 | ||
| A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity | Q39785306 | ||
| Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression | Q39835934 | ||
| Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation | Q40130351 | ||
| Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors | Q40338282 | ||
| Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes | Q40619033 | ||
| The huPBL-SCID mouse as a means to examine human immune function in vivo | Q41179011 | ||
| Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies | Q41581372 | ||
| Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma | Q42833240 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. | Q43678706 | ||
| Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions | Q45126833 | ||
| Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells | Q45862006 | ||
| T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients | Q45876112 | ||
| CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. | Q45984095 | ||
| Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. | Q49094344 | ||
| Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains. | Q51805063 | ||
| Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. | Q53659254 | ||
| Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients | Q61831538 | ||
| Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide | Q70215333 | ||
| B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes | Q70437885 | ||
| Use of monoclonal anti-mouse immunoglobulin to detect mouse antibodies | Q71650396 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3875-3886 | |
| P577 | publication date | 2010-07-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells | |
| P478 | volume | 116 |
| Q37201423 | "Model t" cells: a time-tested vehicle for gene therapy |
| Q36356392 | A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity |
| Q100736907 | A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia |
| Q90124449 | A versatile flow-based assay for immunocyte-mediated cytotoxicity |
| Q27006934 | Adoptive T-cell therapy for Leukemia |
| Q28262548 | Adoptive immunotherapy for cancer: harnessing the T cell response |
| Q36321054 | Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape |
| Q35904666 | Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease |
| Q64935147 | Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. |
| Q38666304 | An Update on the Use of Immunotherapy in the Treatment of Lymphoma |
| Q36619703 | Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia |
| Q27011298 | Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors |
| Q35604043 | Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma |
| Q55340132 | Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. |
| Q46082373 | Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. |
| Q29620717 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells |
| Q36778126 | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma |
| Q38170499 | CAR T cells: driving the road from the laboratory to the clinic. |
| Q89481529 | CAR T-cell product performance in haematological malignancies before and after marketing authorisation |
| Q46018826 | CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia. |
| Q38164792 | CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road |
| Q37153598 | CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity |
| Q34667972 | CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. |
| Q27011836 | CD19 as an attractive target for antibody-based therapy |
| Q29620607 | CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia |
| Q36777155 | CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice |
| Q59809962 | CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia |
| Q90596725 | Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency |
| Q38794293 | Cell and gene therapy strategies to eradicate HIV reservoirs |
| Q36257036 | Challenges and opportunities of allogeneic donor-derived CAR T cells |
| Q38823847 | Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma. |
| Q34041792 | Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor |
| Q26799357 | Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street |
| Q39272183 | Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective |
| Q57169017 | Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes |
| Q64054386 | Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel |
| Q85800899 | Chimeric antigen receptor T cells for ALL |
| Q38600697 | Chimeric antigen receptor T-cell therapies for lymphoma |
| Q47776210 | Chimeric antigen receptor T-cell therapies for multiple myeloma |
| Q90349845 | Chimeric antigen receptor T-cell therapies: Optimising the dose |
| Q55443158 | Chimeric antigen receptor T‑cell therapy—a hematological success story. |
| Q38096540 | Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? |
| Q93073831 | Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development |
| Q37952805 | Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions |
| Q93166160 | Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy |
| Q34511646 | Clinical application of genetically modified T cells in cancer therapy |
| Q41915301 | Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model |
| Q33955720 | Current status of cancer immunotherapy |
| Q27024456 | Current translational and clinical practices in hematopoietic cell and gene therapy |
| Q92354573 | Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma |
| Q39391468 | Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies |
| Q41131801 | Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. |
| Q37390239 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation |
| Q37618652 | EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. |
| Q33587034 | Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells |
| Q30252944 | Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. |
| Q38344404 | Emerging drugs for diffuse large B-cell lymphoma |
| Q39718346 | Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia |
| Q92059900 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy |
| Q90660671 | Excessive costimulation leads to dysfunction of adoptively transferred T cells |
| Q50027691 | Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains |
| Q41625041 | GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity |
| Q37950928 | GUCY2C-targeted cancer immunotherapy: past, present and future. |
| Q38123667 | Gene-engineered T cells for cancer therapy |
| Q57789220 | Glypicans as Cancer Therapeutic Targets |
| Q28088598 | Harnessing the Microbiome to Enhance Cancer Immunotherapy |
| Q39398719 | Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy |
| Q36923835 | Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. |
| Q47947865 | High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model |
| Q36476104 | How do CARs work?: Early insights from recent clinical studies targeting CD19. |
| Q88594789 | Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice |
| Q36727794 | IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells |
| Q50004232 | IL-2 and Beyond in Cancer Immunotherapy |
| Q26865561 | Immune reconstitution in chronic lymphocytic leukemia |
| Q55257180 | Immunotherapeutic interventions of Triple Negative Breast Cancer. |
| Q34219970 | Immunotherapy for metastatic solid cancers |
| Q33593865 | Immunotherapy in hematologic malignancies: past, present, and future |
| Q37263151 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study |
| Q61135664 | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens |
| Q88573561 | Introduction to a review series on emerging immunotherapies for hematologic diseases |
| Q38797183 | Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. |
| Q38147100 | Lentiviral vectors for cancer immunotherapy and clinical applications |
| Q36845805 | Lessons learned from a highly-active CD22-specific chimeric antigen receptor |
| Q39435163 | Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells |
| Q40095482 | Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy |
| Q90286096 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial |
| Q26782902 | Lymphoma Immunotherapy: Current Status |
| Q50034163 | Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. |
| Q35181705 | Mouse model for pre-clinical study of human cancer immunotherapy. |
| Q38218786 | Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. |
| Q36675086 | Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. |
| Q52603959 | Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment. |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q91987008 | NR4A transcription factors limit CAR T cell function in solid tumours |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q35568556 | Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers |
| Q38568358 | Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? |
| Q36212699 | Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells |
| Q88762973 | Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans |
| Q90355383 | Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management |
| Q36321176 | Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma |
| Q42559059 | Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia |
| Q92784793 | Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma |
| Q38207986 | Sarcoma immunotherapy: past approaches and future directions |
| Q90216600 | Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification |
| Q92765883 | Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity |
| Q39790928 | Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy |
| Q35177618 | Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy |
| Q35265135 | Supportive care in patients with acute leukaemia: historical perspectives |
| Q58106930 | Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory |
| Q37506182 | Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice |
| Q88891955 | T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma |
| Q36965071 | T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies |
| Q40096913 | T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma |
| Q52689465 | T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. |
| Q48250863 | TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. |
| Q94545537 | Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells |
| Q39026731 | Targeting high-grade B cell lymphoma with CD19-specific T cells |
| Q41442041 | The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies |
| Q36547199 | The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies |
| Q57177485 | The application of CAR-T cell therapy in hematological malignancies: advantages and challenges |
| Q56980290 | The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity |
| Q49276632 | The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells |
| Q57278479 | Therapeutic Impact of Immune Responses in Cancer |
| Q40199809 | Therapeutic T cell engineering |
| Q96022761 | Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus |
| Q45868285 | Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants |
| Q38839878 | Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors |
| Q38094968 | Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. |
| Q42702234 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q26785545 | Trial Watch: Adoptive cell transfer for oncological indications |
| Q35986612 | Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning |
| Q39045535 | Tumor-targeting domains for chimeric antigen receptor T cells |
| Q34045831 | Versatile strategy for controlling the specificity and activity of engineered T cells |
| Q94453577 | Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy |
Search more.